Fig. 1From: PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancersIllustrated diagram describing DNA repair pathways. (Note: BER, base excision repair; DSB, double strand break; HRR, homologous recombination repair; NER, nucleoside excision repair; NHEJ, non-homologous end-joining; SSB, single strand break)Back to article page